Loading company
Loading
Latest annual · FY2025
Millions- Total revenues
- 1
- Operating income
- (60)
- Net income
- (60)
- Free cash flow
- (46)
Latest quarter · Q2 FY2026
Millions- Free cash flow
- (7)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -6.4%
- Revenue, 5 yearsFY2020 to FY2025
- +1.3%
- Net income, 5 yearsFY2020 to FY2025
- n/m
NORTHWEST BIOTHERAPEUTICS INC (NWBO) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $1.4 million | $1.4 million | -0.3% | 10-K 2026-04-15 · proof |
| Operating income | -$59.9 million | -$66.5 million | 10-K 2026-04-15 · proof | |
| Net income | -$60.2 million | -$83.8 million | 10-K 2026-04-15 · proof | |
| Cash from operating activities | -$44.8 million | -$57 million | 10-K 2026-04-15 · proof | |
| Free cash flow | -$46.3 million | -$58 million | 10-K 2026-04-15 · proof | |
| Total assets | $81.3 million | $26.7 million | +204.1% | 10-K 2026-04-15 · proof |
| Total liabilities | $128.9 million | $105.7 million | +21.9% | 10-K 2026-04-15 · proof |
| Cash and cash equivalents | $3 million | $2.2 million | +39.8% | 10-K 2026-04-15 · proof |
- What was NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s revenue in fiscal 2025?
- NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported revenue of $1.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $1.4 million the year before (-0.3%). Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What was NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s operating income in fiscal 2025?
- NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported operating income of -$59.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$66.5 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What was NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s net income in fiscal 2025?
- NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported net income of -$60.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$83.8 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What was NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s cash from operating activities in fiscal 2025?
- NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported cash from operating activities of -$44.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$57 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What was NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s free cash flow in fiscal 2025?
- NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported free cash flow of -$46.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$58 million the year before. Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What are NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s total assets?
- As of Dec 31, 2025, NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported total assets of $81.3 million, against $26.7 million a year earlier (+204.1%). Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What are NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s total liabilities?
- As of Dec 31, 2025, NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported total liabilities of $128.9 million, against $105.7 million a year earlier (+21.9%). Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
- What are NORTHWEST BIOTHERAPEUTICS INC (NWBO)'s cash and cash equivalents?
- As of Dec 31, 2025, NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported cash and cash equivalents of $3 million, against $2.2 million a year earlier (+39.8%). Source: the 10-K filed with the SEC on Apr 15, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:NWBO&period_type=annual&limit=5"Information only, not investment advice.